Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases.

Abstract

AIM:

To investigate the impact of RAS and BRAF mutations on the pattern of metastatic disease and carcinoembryonic antigen (CEA) production.

METHODS:

In this retrospective study, we investigated the impact of RAS and BRAF mutational status on pattern of metastatic disease and CEA production. Only patients presenting with a newly diagnosed metastatic colorectal cancer (CRC) were included. Patients' characteristics, primary tumor location, site of metastatic disease and CEA at presentation were compared between those with and without RAS and BRAF mutations.

RESULTS:

Among 174 patients, mutations in KRAS, NRAS and BRAF were detected in 47%, 3% and 6% respectively. RAS mutations (KRAS and NRAS) were more likely to be found in African American patients (87% vs 13%; P value = 0.0158). RAS mutations were associated with a higher likelihood of a normal CEA (< 5 ng/mL) at presentation. BRAF mutations were more likely to occur in females. We were not able to confirm any association between mutational status and site of metastatic disease at initial diagnosis.

CONCLUSION:

No association was found between RAS and BRAF mutations and sites of metastatic disease at the time of initial diagnosis in our cohort. Patients with RAS mutations were more likely to present with CEA levels < 5 ng/mL. These findings may have clinical implications on surveillance strategies for RAS mutant patients with earlier stages of CRC.

• Authors: May Cho, Chie Akiba, Cecilia Lau, David Smith, Milhan Telatar, Michelle Afkhami, Stephen Sentovich, Kurt Melstrom, Marwan Fakih
• Journal: World journal of gastrointestinal oncology (World J Gastrointest Oncol) Vol. 8 Issue 1 Pg. 128-35 (Jan 15 2016) ISSN: 1948-5204 [Print] China
• PMID: 26798444 (Publication Type: Journal Article)